Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis
- PMID: 19461510
- PMCID: PMC2716424
- DOI: 10.1097/PAS.0b013e3181a24354
Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis
Abstract
A 2-tier grading system based on nuclear grade divides ovarian serous carcinomas into low (nuclear grade 1) and high grade (nuclear grade 3). In most instances the separation is straightforward but at times, the morphologic distinction between them can be difficult. We studied 11 ovarian serous carcinomas with features that were "intermediate" (nuclear grade 2) between low and high grade. All the cases were high staged and had a poor clinical outcome. None of the tumors showed mutations in KRAS, BRAF, and ERBB2 genes that characterize most low-grade serous carcinomas. In contrast, 10 (90.9%) of 11 cases contained nonsynonymous TP53 mutations characteristic of high-grade serous carcinomas. In summary, the molecular genetic profile and behavior of serous carcinomas with grade 2 nuclei are virtually the same as those of serous carcinomas with grade 3 nuclei, supporting the use of the 2-tier grading system for classifying ovarian serous carcinomas.
Figures




Similar articles
-
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Adv Anat Pathol. 2009. PMID: 19700937 Free PMC article. Review.
-
Molecular characterization of 103 ovarian serous and mucinous tumors.Pathol Oncol Res. 2011 Sep;17(3):551-9. doi: 10.1007/s12253-010-9345-8. Epub 2010 Dec 7. Pathol Oncol Res. 2011. PMID: 21136228
-
Low-grade serous carcinomas of the ovary contain very few point mutations.J Pathol. 2012 Feb;226(3):413-20. doi: 10.1002/path.3967. Epub 2011 Dec 20. J Pathol. 2012. PMID: 22102435 Free PMC article.
-
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.Am J Surg Pathol. 2007 Jul;31(7):1007-12. doi: 10.1097/PAS.0b013e31802cbbe9. Am J Surg Pathol. 2007. PMID: 17592266
-
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Cancer Treat Rev. 2015. PMID: 25573350 Review.
Cited by
-
Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.PLoS One. 2013;8(3):e57799. doi: 10.1371/journal.pone.0057799. Epub 2013 Mar 11. PLoS One. 2013. PMID: 23536770 Free PMC article.
-
Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.Int J Gynecol Pathol. 2011 Nov;30(6):553-68. doi: 10.1097/PGP.0b013e31821f4b85. Int J Gynecol Pathol. 2011. PMID: 21979592 Free PMC article. Review.
-
Gene expression profile association with poor prognosis in epithelial ovarian cancer patients.Sci Rep. 2021 Mar 8;11(1):5438. doi: 10.1038/s41598-021-84953-9. Sci Rep. 2021. PMID: 33686173 Free PMC article. Clinical Trial.
-
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.PLoS One. 2013;8(2):e54103. doi: 10.1371/journal.pone.0054103. Epub 2013 Feb 4. PLoS One. 2013. PMID: 23390495 Free PMC article.
-
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.Mol Cancer. 2015 Nov 17;14:196. doi: 10.1186/s12943-015-0464-4. Mol Cancer. 2015. PMID: 26576679 Free PMC article.
References
-
- Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand. 1971;50:1–7. - PubMed
-
- Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678–81. - PubMed
-
- Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–8. - PubMed
-
- Hsu CY, Kurman RJ, Vang R, et al. Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Hum Pathol. 2005;36:1049–54. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous